Subcutaneous Immunoglobulin in Oncology Clinical Practice

The administration of gammaglobulin as replacement therapy to boost immune function in patients with immunodeficiency secondary to malignancy is traditionally given in the IV formulation. A pilot program at a large Canadian cancer center led by an advanced practice nurse (APN) demonstrated that transitioning patients to home-based, self-administered subcutaneous infusions (subcutaneous immunoglobulin [SCIG]) led to savings and benefits for patients and the institution. The implementation of SCIG in oncology by an APN is a novel and innovative patient-centered approach to supportive care.

At a Glance

• Replacement therapy of gammaglobulin may be safely administered via slow subcutaneous infusions in the home setting.
• Transitioning patients from IV gammaglobulin to SCIG promotes patient engagement, independence, and autonomy.
• Development, implementation, and evaluation of an SCIG program represents one role an APN can play in oncology clinical care.